CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0065 (clinicaltrials.gov NCT No: NCT01523171)
Title:A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Principal Investigator:Jorge Cortes
Treatment Agent:SAR302503
Study Status:Closed
Study Description:You are currently taking part in the 2012-0065 research study. The purpose of
this form is to tell you about new information about the study drug that
affects your participation in this study.

This form is an addendum to the informed consent you previously signed in order
to participate in this clinical trial.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:SAR302503
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:sanofi aventis
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
Dept:Leukemia
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults